Douglas W. Calder

BioVest International, Inc. develops and commercializes personalized therapeutic cancer vaccine for the treatment of B-cell blood cancers. The firm continued development, commercialization, manufacture and sale of AutovaxID and other instruments and disposables; and the commercial sale and production of cell culture products and services. The company was founded in 1981 and is headquartered in Tampa, FL.

Accentia Biopharmaceuticals, Inc. engages in the commercialization of patent-protected disruptive healthcare technologies. It offers products under the BiovaxID., Revimmune, and SinuNase brands. The company was founded in 2002 and is headquartered in Tampa, FL.

BioFlorida, Inc. is an organization that represents the life science industry in Florida. The private company is based in Florida and represents over 6,700 establishments and research organizations in the biopharmaceutical, medical technology, and bioagriculture sectors, providing employment to 94,000 Floridians. The American company's initiatives aim to create a favorable business environment for the development of innovative products and technologies that enhance people's lives and bring economic benefits to the state. Nancy K. Bryan has been the CEO of the company since 2013.

Vycellix, Inc. is a life science company that specializes in the development of cell and gene-based therapies for various medical conditions such as hematology/oncology, autoimmunity/chronic inflammatory diseases, and organ/tissue transplantation. The private company is based in Tampa, FL. The company's platforms were discovered by scientists at the Karolinska Institutet in Sweden, which is known for its Nobel Assembly. Vycellix is headquartered in the United States, with scientific operations in Sweden. The company's mission is to develop and commercialize optimized, next-generation T cell and natural killer (NK) cell-based cancer therapies using its transformational Vy-UC universal cell technology. The CEO of the company is Evren Alici.